antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Company profile
Ticker
XNCR
Exchange
Website
CEO
Bassil Dahiyat
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
201622502
XNCR stock data
Latest filings (excl ownership)
8-K
Xencor Reports First Quarter 2024 Financial Results
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Xencor Appoints Bart Cornelissen as Chief Financial Officer
9 Apr 24
8-K
Regulation FD Disclosure
6 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Entry into a Material Definitive Agreement
15 Nov 23
Transcripts
XNCR
Earnings call transcript
2023 Q4
27 Feb 24
XNCR
Earnings call transcript
2023 Q3
7 Nov 23
XNCR
Earnings call transcript
2023 Q2
3 Aug 23
XNCR
Earnings call transcript
2023 Q2
3 Aug 23
XNCR
Earnings call transcript
2023 Q1
8 May 23
XNCR
Earnings call transcript
2022 Q4
23 Feb 23
XNCR
Earnings call transcript
2022 Q3
8 Nov 22
XNCR
Earnings call transcript
2022 Q2
4 Aug 22
XNCR
Earnings call transcript
2022 Q1
8 May 22
XNCR
Earnings call transcript
2021 Q4
24 Feb 22
Latest ownership filings
4
Nancy Valente
3 May 24
144
Notice of proposed sale of securities
2 May 24
4
Bart Jan Cornelissen
11 Apr 24
3
Bart Jan Cornelissen
11 Apr 24
4
John J Kuch
12 Mar 24
4
Celia Eckert
12 Mar 24
4
John R Desjarlais
12 Mar 24
4
Bassil I Dahiyat
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.42 mm | 31.42 mm | 31.42 mm | 31.42 mm | 31.42 mm | 31.42 mm |
Cash burn (monthly) | 7.58 mm | 3.41 mm | 19.29 mm | 11.93 mm | 18.42 mm | (no burn) |
Cash used (since last report) | 13.36 mm | 6.02 mm | 33.98 mm | 21.02 mm | 32.45 mm | n/a |
Cash remaining | 18.05 mm | 25.40 mm | -2.56 mm | 10.40 mm | -1.04 mm | n/a |
Runway (months of cash) | 2.4 | 7.4 | -0.1 | 0.9 | -0.1 | n/a |
Institutional ownership, Q1 2024
6.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 72 |
Opened positions | 14 |
Closed positions | 85 |
Increased positions | 21 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 65.78 bn |
Total shares | 3.72 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Candriam Luxembourg S.C.A. | 651.32 k | $14.41 bn |
Stafford John S Iii | 551.53 k | $17.58 mm |
BK Bank Of New York Mellon | 484.73 k | $10.73 bn |
PFG Principal Financial Group Inc - Registered Shares | 323.67 k | $7.16 bn |
Russell Investments | 224.14 k | $4.96 bn |
Panagora Asset Management | 212.33 k | $4.70 bn |
TD Asset Management | 143.45 k | $3.17 bn |
State of New Jersey Common Pension Fund D | 107.77 k | $2.39 bn |
Swiss National Bank | 107.50 k | $2.38 bn |
Mutual Of America Capital Management | 92.51 k | $2.05 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 May 24 | Nancy Valente | Common Stock | Sell | Dispose S | No | No | 23.5768 | 4,745 | 111.87 k | 55,115 |
9 Apr 24 | Bart Jan Cornelissen | Common Stock | Grant | Acquire A | No | No | 0 | 42,265 | 0.00 | 42,265 |
9 Apr 24 | Bart Jan Cornelissen | Stock Option Common Stock | Grant | Acquire A | No | No | 21.55 | 190,194 | 4.10 mm | 190,194 |
11 Mar 24 | John J Kuch | Common Stock | Sell | Dispose S | No | No | 23.5018 | 849 | 19.95 k | 121,070 |
11 Mar 24 | Celia Eckert | Common Stock | Sell | Dispose S | No | No | 23.5018 | 850 | 19.98 k | 45,465 |
News
Decoding 6 Analyst Evaluations For Xencor
10 May 24
Wedbush Maintains Outperform on Xencor, Raises Price Target to $36
10 May 24
Xencor Q1 2024 GAAP EPS $(1.11) Misses $(0.78) Estimate, Sales $12.805M Miss $24.992M Estimate
9 May 24
Analyst Scoreboard: 6 Ratings For Xencor
16 Apr 24
BTIG Maintains Buy on Xencor, Lowers Price Target to $38
16 Apr 24